Inhibition of Stearoyl-CoA desaturase 1 reverts BRAF and MEK inhibition-induced selection of cancer stem cells in BRAF-mutated melanoma

被引：0

作者：

Maria Elena Pisanu

Marcello Maugeri-Saccà

Luigi Fattore

Sara Bruschini

Claudia De Vitis

Eugenio Tabbì

Barbara Bellei

Emilia Migliano

Daniela Kovacs

Emanuela Camera

Mauro Picardo

Ziga Jakopin

Claudia Cippitelli

Armando Bartolazzi

Salvatore Raffa

Maria Rosaria Torrisi

Franco Fulciniti

Paolo A. Ascierto

Gennaro Ciliberto

Rita Mancini

机构：

[1] Sapienza University of Rome,Department of Clinical and Molecular Medicine

[2] Division of Medical Oncology 2,Department of Experimental and Clinical Medicine

[3] IRCSS Regina Elena National Cancer Institute,Department of Plastic and Reconstructive Surgery

[4] Preclinical Models and New Therapeutics Agents Unit,undefined

[5] IRCSS Regina Elena National Cancer Institute,undefined

[6] Magna Graecia University of Catanzaro,undefined

[7] Laboratory of Cutaneous Physiopathology and Integrated Center of Metabolomics research,undefined

[8] San Gallicano Dermatologic Institute,undefined

[9] IRCSS,undefined

[10] San Gallicano Dermatologic Institute,undefined

[11] IRCSS,undefined

[12] Faculty of Pharmacy,undefined

[13] University of Ljubljana,undefined

[14] Pathology Research laboratory,undefined

[15] Sapienza University,undefined

[16] Sant’Andrea Hospital,undefined

[17] Cellular Diagnostics Unit,undefined

[18] Sapienza University,undefined

[19] Sant’Andrea Hospital,undefined

[20] Istituto Cantonale di Patologia,undefined

[21] Servizio di Citologia Clinica,undefined

[22] Melanoma,undefined

[23] Cancer Immunotherapy and Development Therapeutics Unit,undefined

[24] Istituto Nazionale Tumori IRCCS Fondazione “G. Pascale”,undefined

[25] Scientific Directorate,undefined

[26] Istituto Nazionale Tumori IRCSS Regina Elena,undefined

[27] Present Address: High Resolution NMR Unit,undefined

[28] Core Facilities,undefined

[29] Istituto Superiore di Sanità,undefined

来源：

Journal of Experimental & Clinical Cancer Research | / 37卷

关键词：

Lipid metabolism; Melanoma cancer stem cells; BRAF; MEK inhibitors;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 300 条

[1]

Wahid M(2018)Recent developments and obstacles in the treatment of melanoma with BRAF and MEK inhibitors Crit Rev Oncol Hematol 125 84-88

[2]

Jawed A(2017)Targeted agents and immunotherapies: optimizing outcomes in melanoma Nat Rev Clin Oncol 8 463-482

[3]

Mandal RK(2017)Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials Eur J Cancer 82 45-55

[4]

Dar SA(2015)Improved overall survival in melanoma with combined dabrafenib and trametinib N Engl J Med 1 30-39

[5]

Akhter N(2016)Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial Lancet Oncol. 9 1248-1260

[6]

Somvanshi P(2018)Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial Lancet Oncol 5 603-615

[7]

Luke JJ(2012)Combinatorial therapies to overcome B-RAF inhibitor resistance in melanomas Future Medicine 13 2-424

[8]

Flaherty KT(2012)Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors Cancer Discov. 5 414-977

[9]

Ribas A(2012)Melanoma whole-exome sequencing identifies (V600E) B-RAF amplification-mediated acquired B-RAF inhibitor resistance Nat Commun 3 724-390

[10]

Long GV(2010)Melanomas acquires resistance to BRAF (V600E) inhibition by RTK or N-RAS upregulation Nature 7326 973-829

← 1 2 3 4 5 6 7 8 9 10 →